secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cue Biopharma, Inc. (CUE)
CIK:        0001645460
Form:       8-K
Filed at:   2025-06-10T23:59:59+00:00
Accession:  0000950170-25-084279
Event type: leadership
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.02, 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cue Biopharma CFO resigns, elects Jill Broadfoot to board, increases authorized shares to 310M
--------------------------------------------------------------------------------

- CFO Kerri-Ann Millar resigns effective June 13, 2025; CEO Daniel Passeri will be interim principal financial and accounting officer.
- Jill Broadfoot appointed to board and Audit Committee chair; granted option to purchase 48,800 shares.
- Authorized shares of capital stock increased from 210M to 310M; common stock from 200M to 300M.
- Stockholders approved 2025 Stock Incentive Plan (13.85M for, 2.01M against); also elected all director nominees.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645460/000095017025084279/0000950170-25-084279-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645460/000095017025084279/cue-20250604.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-084279

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer